Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | RXRB | P28702 | 4/20 | 0.42 |
| ▸ | RXRG | P48443 | 4/20 | 0.42 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773380 | 0.90 | FFAR1 (0.45) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5773868 | 0.88 | RXRA (0.53) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5774825 | 0.88 | FFAR1 (0.42) | FFAR1TSHRFFAR4 | |
| SCHEMBL5777338 | 0.86 | CCNC (0.41) | FFAR1RPA1 | |
| SCHEMBL5775401 | 0.85 | FFAR1 (0.40) | FFAR1TSHRFFAR4 | |
| SCHEMBL5772923 | 0.84 | TSHR (0.55) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5768932 | 0.84 | FFAR1 (0.43) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5777600 | 0.82 | RXRA (0.42) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5773615 | 0.82 | RXRA (0.56) | FFAR1TSHRRXRARXRBRXRG | |
| SCHEMBL5770999 | 0.82 | SIRT2 (0.40) | RPA1FFAR4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | FFAR1 178/4885TSHR 534/4885RXRA 445/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | FFAR1 90/4885TSHR 583/4885RXRA 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.